Introduction to the Impact of Resistance in Hepatitis C

Size: px
Start display at page:

Download "Introduction to the Impact of Resistance in Hepatitis C"

Transcription

1 Introduction to the Impact of Resistance in Hepatitis C Sponsored by AbbVie 2/1/2017 Presented by Sammy Saab, MD, MPH, FACG, AGAF, FAASLD February 1 st,

2 AbbVie disclosures This is an Abbvie sponsored educational webinar which is being presented by Sammy Saab, MD, on behalf of AbbVie The purpose of this medical educational webinar is to foster increased awareness of the latest science in the management of HCV HCV, hepatitis C virus. Speaker disclosures Speakers Bureau and Consultant: AbbVie, BMS, Gilead, Merck, Intercept 2

3 Contents How does HCV resistance arise? How long do treatment emergent RASs persist? How often should physicians expect to see RASs in clinical practice? How does a physician test for virologic resistance? Summary RAS, resistance associated substitution. How does HCV resistance arise? 3

4 HCV has high genetic heterogeneity HCV has an inherently high mutation rate that results in considerable heterogeneity throughout the genome 1,2 High mutability is caused by: HCV lifecycle A high viral replication rate, with the production and clearance of to virions per day 1 4 NS5B RNA polymerase has poor fidelity and lacks proofreading activity, resulting in a high rate (10 3 to 10 5 ) of misincorporations per nucleotide per replication 1 RNA, ribonucleic acid. 1. Sarrazin C, et al. Gastroenterology. 2010;138: Bartenschlager R, et al. J Gen Virol. 2000;81: Herrmann E, et al. Antivir Ther. 2000;5: Neumann AU, et al. Science. 1998;282: Image reproduced from Lindenbach BD, et al. Nature. 2005;436: DAAs target 1 of 3 viral proteins: NS3/4A, NS5A, and NS5B 1,2 NS5A protein Component of the HCV replication complex NS3/4A protease Viral protein production NS5B polymerase HCV replication DAA, direct acting antiviral. 1. Bartenschlager R, et al. J Gen Virol. 2000;81: Pawlotsky JM. Gastroenterology. 2016;151: Image reproduced from Lindenbach BD, et al. Nature. 2005;436:

5 Terminology and definitions Variant: a viral particle, which may or may not be resistant to a particular drug Polymorphism: a naturally occurring change in the viral genome, which may or may not result in an amino acid change in the resulting protein RAP (resistance associated polymorphism): an amino acid change that results in resistance to a drug; occurs naturally, ie, without drug exposure RAS (resistance associated substitution): an amino acid change that results in resistance to a drug; occurs under selection pressure of DAA treatment Resistant variant: a variant carrying one or more RASs The term RAV (resistance associated variant) is used interchangeably in the literature to refer to both RASs and the resistant variants which carry them. This term is inaccurate and should no longer be used Pawlotsky JM. Gastroenterology. 2016;151: RASs develop as a result of changes in the nucleotide sequence of codons HCV genome 1 p C E1 E2 7 NS2 NS3 NS NS4B NS5A NS5B 5 UTR 4A 3 UTR NS5A domain 1 (213 amino acids for GT1) Example: Codon 93 of HCV NS5A 2,3 mrna Amino acid Codon 93 Codon 93 UAC Tyr (Y) Y93 Wild type Nucleotide substitution A codon is a sequence of 3 nucleotides in a DNA or RNA molecule (eg, UAC) that code for a single amino acid (eg, tyrosine) in a protein (eg, NS5A) 3,4 DNA, deoxyribonucleic acid; GT, genotype; UTR, untranslated region. 1. Ahmed A, Felmlee DJ. Viruses. 2015;7: Lontok E, et al. Hepatology. 2015;62: OpenStax College. Chapter 3: Biological Macromolecules. OpenStax College, Biology. Dec 19, 2016: Available at: prodcms/media/documents/biology OP.pdf. Accessed January OpenStax College. Chapter 15: Genes and Proteins. OpenStax College, Biology. Dec 19, 2016: Available at: prodcms/media/documents/biology OP.pdf. Accessed January CAC His (H) Y93H NS5A RAS A change in a codon can result in a different amino acid being incorporated into the protein 3,4 5

6 These codon changes can result in a change in the interaction between the viral protein and the DAA Wild type protein Variant protein DAA DAA Impaired binding Factors that determine the barrier to resistance to a particular DAA: 2 Binding affinity of the DAA for its target site Potency and pharmacokinetics of the DAA HCV genotype and subtype Patient adherence to the DAA regimen Impaired binding of the DAA to the protein may result in reduced efficacy 1 1. Romano KP, et al. PLoS Pathog. 2012;8:e Sarrazin C, et al. Gastroenterology. 2010;138: Drug susceptibility of resistant variants depends on the genetic barrier to resistance The genetic barrier to resistance to a particular antiviral agent is the number and type of nucleotide changes required for a variant to acquire clinical resistance to the antiviral agent 1,2 HCV is more prone to developing resistance than 2 Example: R155 in the NS3/4A protease PAGHAVGIFRAAVCTRGVAKAVDFIP S V AGA AAA (R155K) AGA ACA (R155T) CGA AAA (R155K) CGA ACA (R155T) Selection of R155K/T requires 1 mutation in Selection of R155K/T requires 2 mutations in 1. Pawlotsky JM. Gastroenterology. 2016;151: Perales C, et al. Viruses. 2015;7:

7 Outgrowth of resistant variants depends on fitness The fitness of a variant is its ability to replicate, and is independent of the drug resistance conferred by the RASs it carries Fitness associated substitutions can be naturally present or emerge during DAA therapy Fitness associated substitutions may increase the fitness of resistant variants, leading to their rapid outgrowth during treatment (breakthrough) or after treatment (relapse) During treatment, outgrowth of resistant variants depends more on their fitness than on the level of resistance conferred by the RASs they carry. After treatment, competition for growth between the variants also depends on their relative fitness Pawlotsky JM. Gastroenterology. 2016;151: Inadequate drug pressure can select for resistant variants and may contribute to treatment failure 1,2 Treatment Post treatment Viral load Selection of resistant variants Drug susceptible variants Drug resistant variants Patients begin treatment with viral variants Time Virologic failure 1. Ahmed A, et al. Viruses. 2015;7: Forum for Collaborative HIV Research and HCV Drug Development Advisory Group (HCV DrAG ResisSS 2013 v.1). #2 HCV Resistance: Barriers, Selection and Monitoring of Resistance. Aug 12, Available at: 0and%20monitoring%20of%20resistance_8_8.pdf. Accessed January

8 Inadequate drug pressure can select for resistant variants and may contribute to treatment failure 1,2 Treatment Post treatment Viral load Selection of resistant variants Drug susceptible variants Drug resistant variants Following treatment failure, drug susceptible variants may begin to re emerge Time Patients begin treatment Virologic failure with viral variants The timeline for re emergence depends on the viral fitness of resistant variants 1. Ahmed A, et al. Viruses. 2015;7: Forum for Collaborative HIV Research and HCV Drug Development Advisory Group (HCV DrAG ResisSS 2013 v.1). #2 HCV Resistance: Barriers, Selection and Monitoring of Resistance. Aug 12, Available at: 0and%20monitoring%20of%20resistance_8_8.pdf. Accessed January How long do treatmentemergent RASs persist? 8

9 Persistence of RASs post treatment NS5A RASs tend to persist far longer than those of NS3 and NS5B RASs (%) Estimated clearance time for RASs NS5A inhibitors <50% of NS3 RASs persist 24 weeks PT >95% of NS5A RASs persist 48 weeks PT <60% of NS5B RASs persist 48 weeks PT <10% of NS3 RASs persist 48 weeks PT Days Weeks post treatment PT, post treatment. Pawlotsky JM. Gastroenterology. 2016;151: How treatments can overcome resistance Drug susceptible virus Drug resistant virus Increase treatment duration and/or add additional agents Viral load If reliable tests are available, conduct resistance testing to determine the most appropriate retreatment regimen Use DAA combination therapy with multiple MOAs* Time MOA, mechanism of action. *Note that DAA monotherapy is not recommended in any clinical scenario. AASLD ISDA. Recommendations for Testing, Managing, and Treating Hepatitis C. Oct Available at: Guidance_October_2016_a.pdf. Accessed January EASL Recommendations on Treatment of Hepatitis C J Hepatol. 2017;66:

10 How often should physicians expect to see RASs in clinical practice? Prevalence of frequently observed protease inhibitor (NS3/4A) RASs by population sequencing Overall prevalence of baseline NS3 RASs 1 * Prevalence of key baseline NS3 RASs 2 48 Prevalence (%) Many NS3 RASs do not confer high resistance to NS3 inhibitors 3 *Data from a Phase 3 trial of an NS3 containing DAA combination regimen in treatment naïve HCV GT1 infected individuals. Baseline NS3 resistance data was available for 151 and 129 patients. 1 RASs with a >2 fold change in comparison to wild type in a phenotypic assay. 1. Zeuzem S, et al. Ann Intern Med. 2015;163: Sarrazin C. J Hepatol. 2016;64: Lontok E, et al. Hepatology 2015; 62:

11 Prevalence (%) Prevalence of frequently observed NS5A RASs by NGS sequencing (15% cutoff) Overall prevalence of baseline NS5A RASs* Prevalence of key baseline NS5A RASs (North America only)* 11 n.a., not applicable. *Pooled data from 5 Phase 3 trials of an NS5A containing DAA combination regimen in HCV GT1 infected individuals. Baseline NS5A resistance data were available for 420 and 143 patients. Sarrazin C, et al. J Hepatol. 2016;64(Suppl):S214 (EASL 2016; poster #LBP503. Available at: Accessed January 2017) Q30E/R 1.1 L31M 8.7 M28T/V Y93 (any) n.a Q30E/R L31M/V M28T/V n.a Y93 (any) Prevalence (%) Prevalence of frequently observed NS5B RASs by NGS sequencing (15% cutoff) Overall prevalence of baseline NS5B RASs 1 * Most NS5B RASs confer minimal impact on resistance 2,3 Prevalence of key baseline NS5B RASs In HCV infected patients 1 * *Pooled data from 5 Phase 3 trials of an NS5B containing DAA combination regimen in HCV GT1 infected individuals. Baseline NS5B resistance data were available for 145 patients. 1. Sarrazin C, et al. J Hepatol. 2016;64(Suppl):S214 (EASL 2016; poster #LBP503. Available at: Accessed January 2017). 2. Sarrazin C. J Hepatol. 2016;64: Lontok E, et al. Hepatology 2015; 62: N.Am. Eur. ROW N.Am. Eur. ROW C316N S556G 11

12 How does a physician test for virologic resistance? Testing for HCV Resistance Resistance testing requires PCR amplification of large fragments of the genes encoding the NS3 protease, NS5A protein, and NS5B protein In contrast to HIV resistance tests, no standardized assays* for HCV resistance are available as purchasable kits and in house techniques based on population or deep sequencing may be used Alternatively, there are a number of reference laboratories that have made such tests available in the USA and Europe (i.e. Monogram, Quest) HIV, human immunodeficiency virus; PCR, polymerase chain reaction. *Different assays use different primers, reaction conditions, and sequencing cutoffs. Pawlotsky JM. Gastroenterology. 2016;151:

13 RASs can be identified by population based or deep sequencing techniques Population based sequencing 1,2 Next generation sequencing (NGS) 1,2 Sanger method Sensitivity of 10 25% Meaningful, but may not detect all clinically relevant variants Tends to be used in: clinical practice Deep sequencing Sensitivity of ~1% Variants with a prevalence of 15% tend to have poor fitness and may not be clinically relevant Tends to be used in: clinical trials It is likely that a 15% cutoff better predicts treatment failure due to the selection of resistant viruses than a 1% cutoff. A cutoff of 15% is now generally adopted in clinical trials and real world studies, and in clinical practice 2 1. Fourati S, Pawlotsky JM. Viruses. 2015;7: Pawlotsky JM. Gastroenterology. 2016;151: Quest Diagnostics sample report The assays listed on this slide are trademarks of their respective owners and are not trademarks of AbbVie Inc. The makers of these assays are not affiliated with and do not endorse AbbVie Inc. or its products, nor does their inclusion here constitute an endorsement by AbbVie. Quest Diagnostics. Accessed January

14 Monogram Biosciences sample report The assays listed on this slide are trademarks of their respective owners and are not trademarks of AbbVie Inc. The makers of these assays are not affiliated with and do not endorse AbbVie Inc. or its products, nor does their inclusion here constitute an endorsement by AbbVie. Monogram Biosciences. Accessed January Interpretation of HCV resistance will require continued education Tests vary between laboratories 1 The sensitivity of population sequencing varies Cutoffs for deep sequencing are not standardized Not all RASs are clinically meaningful 1 Selection of resistant variants is largely dependent on their fitness with respect to other variants in the population, independent of the RASs they carry 1 The impact of a RAS may differ in treatment naïve and experienced patients, and in those with different disease states (eg, non cirrhotic vs cirrhotic) 2 Overall, the number of possible resistance patterns at baseline is almost infinite, and their potential impact on SVR is unknown 1 SVR, sustained virologic response. 1. Pawlotsky JM. Gastroenterology. 2016;151: Monogram Biosciences. Accessed January

15 Considerations for baseline HCV resistance testing 1. It would be beneficial to have a standardized assay with a sensitivity of 15% as a purchasable kit 1 2. Interpretation and reporting of HCV resistance data should be homogenized and standardized through recommendations by an international organization 1 3. Clinically relevant RASs should be clearly identified as these are most relevant for treatment decisions 1 4. International societies should provide guidelines based on data from clinical trials and real life studies that reported strong predictive values of the different RAS profiles 1 Although routine baseline HCV resistance testing is not currently recommended by AASLD IDSA HCV guidelines, 2 treatment can be optimized for groups of patients known to have specific RASs that reduce response to therapy AASLD, American Association for the Study of Liver Diseases; IDSA, Infectious Diseases Society of America. 1. Pawlotsky JM. Gastroenterology. 2016;151: AASLD ISDA. Recommendations for Testing, Managing, and Treating Hepatitis C. Oct Available at: Guidance_October_2016_a.pdf. Accessed January Summary Resistance can arise from the naturally high mutation rate of HCV RNA polymerase or selective pressure from DAAs Baseline NS5A RASs have been observed in approximately 10 20% of DAA naïve patients The vast majority of NS5A RASs may persist for extended periods of time while NS3 and NS5B RASs typically return to wild type within a year or two The interpretation of HCV resistance tests is challenging due to non standardization of assays and the fact that the impact of RASs on treatment response can depend on multiple factors 15

16 Questions? Please 2/1/

Hepatitis C Resistance Associated Variants (RAVs)

Hepatitis C Resistance Associated Variants (RAVs) Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure

More information

Clinical Applications of Resistance Stuart C. Ray, MD

Clinical Applications of Resistance Stuart C. Ray, MD Clinical Applications of Resistance Stuart C. Ray, MD Professor of Medicine and Oncology Director, Infectious Diseases Fellowship Training Program Johns Hopkins University School of Medicine Disclosures

More information

HCV Resistance Associated variants: impact on chronic hepatitis C treatment

HCV Resistance Associated variants: impact on chronic hepatitis C treatment HCV Resistance Associated variants: impact on chronic hepatitis C treatment Dr. Stéphane Chevaliez Associate Professor of Medicine at the University of Paris-Est. History of Resistance in HCV Concern Only

More information

10/21/2016. David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado

10/21/2016. David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado Drug Resistance-Associated Variants in Hepatitis C Virus Infection: Hype or Help? David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado FORMATTED: 1/3/16

More information

David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado

David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado FORMATTED: 1/3/16 Drug Resistance-Associated Variants in Hepatitis C Virus Infection: Hype or Help? Atlanta, Georgia: October 2, 216 David L. Wyles, MD Chief, Division of Infectious Disease Denver Health

More information

HCV Drug Resistance: Regulatory Perspective

HCV Drug Resistance: Regulatory Perspective HCV Drug Resistance: Regulatory Perspective Patrick Harrington, PhD Senior Clinical Virology Reviewer Division of Antiviral Products, FDA/CDER 2016 HIV and Hepatitis Clinical Pharmacology Workshop Washington,

More information

Is HCV drug resistance an issue?

Is HCV drug resistance an issue? Is HCV drug resistance an issue? 5TH ASIAN CONFERENCE ON HEPATITIS&AIDS NANJING, CHINA 28-29 MAY 2016 FROM BASIC SCIENCE TO CLINICAL PRACTIC Jürgen Kurt Rockstroh Department of Medicine I, University Hospital

More information

Management of HCV in Prior Treatment Failure

Management of HCV in Prior Treatment Failure Management of HCV in Prior Treatment Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners

More information

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,

More information

Utility of Virological Assays at the DAA Era

Utility of Virological Assays at the DAA Era Utility of Virological Assays at the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital

More information

What do we need to know about RAVs clinically?

What do we need to know about RAVs clinically? 14 th European HIV & Hepatitis Workshop Rome, 25-27 May, 2016 What do we need to know about RAVs clinically? Stefan Zeuzem, MD University of Frankfurt Germany Background Resistance associated variants

More information

Virological tools for hepatitis C: re-treatment and resistance. Joop Arends Will Irving. by author

Virological tools for hepatitis C: re-treatment and resistance. Joop Arends Will Irving. by author Virological tools for hepatitis C: re-treatment and resistance Joop Arends Will Irving Disclosures Joop Arends Advisory board: Gilead, Abbvie, Janssen, MSD, BMS (research) grants: Abbvie, BMS, MSD and

More information

HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London

HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown

More information

Baseline and acquired viral resistance to DAAs: how to test and manage

Baseline and acquired viral resistance to DAAs: how to test and manage Baseline and acquired viral resistance to DAAs: how to test and manage Round table discussion by Marc Bourliere, Robert Flisiak, Vasily Isakov, Mark Sulkowsky & Konstantin Zhdanov Prevalence of baseline

More information

Resistencias & Epidemiología. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña

Resistencias & Epidemiología. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña Resistencias & Epidemiología Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña Rapid Evolution of HCV Regimens: Easier to take/tolerate, Short Duration, Pangenotypic,

More information

Clinical utility of NGS for the detection of HIV and HCV resistance

Clinical utility of NGS for the detection of HIV and HCV resistance 18 th Annual Resistance and Antiviral Therapy Meeting v Professor Janke Schinkel Academic Medical Centre, Amsterdam, The Netherlands Thursday 18 September 2014, Royal College of Physicians, London Clinical

More information

Clinical Management: Treatment of HCV Mono-infection

Clinical Management: Treatment of HCV Mono-infection Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry

More information

ICVH 2016 Oral Presentation: 28

ICVH 2016 Oral Presentation: 28 Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K

More information

Direct acting anti-virals: the near future

Direct acting anti-virals: the near future Direct acting anti-virals: the near future Heiner Wedemeyer Hannover Medical School Germany Will IFN-free treatment be possible in the near future? Interferon-free regimens to treat hepatitis C What should

More information

HCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London

HCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,

More information

Need to Assess HCV Resistance to DAAs: Is it Useful and When?

Need to Assess HCV Resistance to DAAs: Is it Useful and When? Need to Assess HCV Resistance to DAAs: Is it Useful and When? Stéphane Chevaliez French National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital

More information

The Changing World of Hepatitis C

The Changing World of Hepatitis C The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures

More information

Disclosures. Advanced HCV management. Overview. Renal failure 1/10/2018. Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH

Disclosures. Advanced HCV management. Overview. Renal failure 1/10/2018. Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH Disclosures Advanced HCV management Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH Overview Renal failure Acute

More information

Virological assessment of patients candidate to DAA

Virological assessment of patients candidate to DAA Virological assessment of patients candidate to DAA Patients characteristics Italian male patient Diagnosis of chronic HCV infection in 1994 Genotype 1b defined in 1998 Non-responder to IFN+RBV He developed

More information

Failure after treatment with DAAs: What to do? Marseille France 2-3 th June 2016

Failure after treatment with DAAs: What to do? Marseille France 2-3 th June 2016 Failure after treatment with DAAs: What to do? Marc Bourliere, MD White Nights of Hepatology Hôpital Saint Joseph Saint Petersburg Marseille France 2-3 th June 16 Disclosures Board member for : Schering-Plough,

More information

NS5A inhibitors: ideal candidates for combination?

NS5A inhibitors: ideal candidates for combination? NS5A inhibitors: ideal candidates for combination? Professor Vasily Isakov, MD, PhD, AGAF Dep.Gastroentrology & Hepatology, ION, Russian Academy of Sciences, Moscow Structure and function of NS5A Meigang

More information

Hepatitis C: Aplicaciones Clínicas de la Resistencia. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña

Hepatitis C: Aplicaciones Clínicas de la Resistencia. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña Hepatitis C: Aplicaciones Clínicas de la Resistencia Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña DAA agents approved or in more advanced stages of clinical

More information

New developments in HCV research and their implications for front-line practice

New developments in HCV research and their implications for front-line practice New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013

More information

New Therapeutic Strategies: Polymerase Inhibitors

New Therapeutic Strategies: Polymerase Inhibitors New Therapeutic Strategies: Polymerase Inhibitors 6th Paris Hepatitis Conference 14 th - 15 th January, 2013 Stefan Zeuzem Goethe University Hospital Frankfurt, Germany Direct antiviral targets C E1 E2

More information

What is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago

What is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate

More information

Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD

Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors

More information

The HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany

The HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany : Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained

More information

Harvoni: solution to HCV

Harvoni: solution to HCV Harvoni: solution to HCV PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP Hepatitis C (HCV) Inflammation of the liver,

More information

2017 UnitedHealthcare Services, Inc.

2017 UnitedHealthcare Services, Inc. UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,

More information

Update in the Management of Hepatitis C: What Does the Future Hold

Update in the Management of Hepatitis C: What Does the Future Hold Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana

More information

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 7 Last Review Date: June 24, 2016 Daklinza Sovaldi Description Daklinza

More information

47 th Annual Meeting AISF

47 th Annual Meeting AISF 47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,

More information

Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy

Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,

More information

HCV In 2015: Maximizing SVR

HCV In 2015: Maximizing SVR HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last

More information

Latest Treatment Updates for GT 2 and GT 3 Patients

Latest Treatment Updates for GT 2 and GT 3 Patients Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of

More information

Eliminating Hepatitis C from New Zealand

Eliminating Hepatitis C from New Zealand Eliminating Hepatitis C from New Zealand Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures I have the following

More information

Protease inhibitor based triple therapy in treatment experienced patients

Protease inhibitor based triple therapy in treatment experienced patients Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber

More information

Viral dynamics and Resistance Implications for HCV drug development

Viral dynamics and Resistance Implications for HCV drug development Viral dynamics and Resistance Implications for HCV drug development Robert T. Schooley, M.D. University of California, San Diego June 23, 2011 SVR Rate Priorities in HCV Therapeutics 100 90 80 70 60 50

More information

Interferon-based and interferon-free new treatment options

Interferon-based and interferon-free new treatment options Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt

More information

HCV NS3 Protease Drug Resistance

HCV NS3 Protease Drug Resistance test code: cpt code: 10000 87902 category: Infectious Disease HCV genotypes 1a CODON Simeprevir 1a Boceprevir 1a Telaprevir 1a Paritaprevir 1a Grazoprevir 1a V36A Comment R 3 R 10, 11 R 16 S 24 V36C V36G

More information

HCV: The next 18 months. David L. Wyles, M.D. Associate Professor of Medicine UCSD

HCV: The next 18 months. David L. Wyles, M.D. Associate Professor of Medicine UCSD HCV: The next 18 months David L. Wyles, M.D. Associate Professor of Medicine UCSD FIRST, A LOOK BACK WHAT DID I SAY LAST YEAR? My predictions for genotype 1: Multiple highly efficacious, well-tolerated,

More information

HCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland

HCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland HCV Infection: EASL Clinical Practice Guidelines 2016 Francesco Negro University Hospital Geneva Switzerland Panel Codinat: Jean-Michel Pawlotsky Panel: Alessio Aghemo David Back Geoffrey Dusheiko Xavier

More information

Azienda ULSS12 Veneziana

Azienda ULSS12 Veneziana Azienda ULSS12 Veneziana Risultati del trattamento dei monoinfetti con Sofosbuvir, Simeprevir nella coorte veneziana. Confronto di esito con la coorte del trattamento con Boceprevir e Telaprevir Dr.ssa

More information

The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients

The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International

More information

Viva La Revolución: Options to Combat Hepatitis C

Viva La Revolución: Options to Combat Hepatitis C Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending

More information

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.36 Subject: Daklinza Page: 1 of 8 Last Review Date: March 18, 2016 Daklinza Description Daklinza (daclatasvir)

More information

Disclosures. I have given sponsored lectures for the following pharmaceutical companies: Gilead, Abbvie and MSD. I own shares of Gilead Sciences.

Disclosures. I have given sponsored lectures for the following pharmaceutical companies: Gilead, Abbvie and MSD. I own shares of Gilead Sciences. Disclosures I have given sponsored lectures for the following pharmaceutical companies: Gilead, Abbvie and MSD. I own shares of Gilead Sciences. Chronic Hepatitis C Prof CL Lai University Department of

More information

Case. 63 year old woman now with:

Case. 63 year old woman now with: Case 63 year old woman now with: HCV GT 1b, HCV RNA 6.2 x 10 6 IU/mL Asymptomatic except for fatigue Normal exam ALT 72 IU/mL, Bili 0.9 mg/dl, INR 1.1, Albumin 3.9 g/dl, Creatinine 0.7 mg/dl Normal EGD

More information

HCV NS5A AND NS5B INHIBITOR RESISTANCE

HCV NS5A AND NS5B INHIBITOR RESISTANCE HCV NS5A AND NS5B INHIBITOR RESISTANCE 13 TH EUROPEAN HIV & HEPATITIS MEETING JUNE 04, 2015 Christos J Petropoulos, PhD Disclosures Christos J Petropoulos is: The Chief Scientific Officer of Monogram Biosciences,

More information

HCV NS3 Protease Drug Resistance

HCV NS3 Protease Drug Resistance test code: cpt code: 10000 87902 category: Infectious Disease HCV genotype 1a CODON Glecaprevir 1a Grazoprevir 1a Paritaprevir 1a Simeprevir 1a Voxilaprevir 1a V36A S 13 R 10 Comment V36C V36G V36I V36L

More information

Genotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty

Genotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn

More information

TREATMENT OF GENOTYPE 2

TREATMENT OF GENOTYPE 2 Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,

More information

Antiviral agents in HCV

Antiviral agents in HCV Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million

More information

Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virus Infected Patients Following TMC435 Monotherapy

Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virus Infected Patients Following TMC435 Monotherapy GASTROENTEROLOGY 212;143:1176 1178 BRIEF REPORTS Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virus Infected Patients Following TMC435 Monotherapy OLIVER LENZ,* JOEP DE BRUIJNE,

More information

Oral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside

Oral combination therapy: future hepatitis C virus treatment? Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following

More information

Express Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011

Express Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011 BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)

More information

Disclosures 29/09/2014. Genetic determinants of. HCV treatment outcome. IDEAL: IL28B-type is the strongest pre-treatment predictor of SVR

Disclosures 29/09/2014. Genetic determinants of. HCV treatment outcome. IDEAL: IL28B-type is the strongest pre-treatment predictor of SVR 29/9/214 Genetic determinants of ᴧ HCV treatment outcome Disclosures Advisory board member - Gilead, Abbvie, Bristol-Myers Squibb (BMS), Janssen, Merck, and oche Speaker - Gilead, Janssen, Merck, BMS,

More information

How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France

How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding

More information

Current Treatments for HCV

Current Treatments for HCV Current Treatments for HCV Mitchell L. Shiffman, MD, FACG Advisory Committee/Board Member: Achillion, Anadys, Boehringer-Ingelheim, BMS, Conatus, Genentech, Gen-Probe, Gilead, Globeimmune, GSK, Janssen,

More information

Clinical Criteria for Hepatitis C (HCV) Therapy

Clinical Criteria for Hepatitis C (HCV) Therapy Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy

More information

Hepatitis C Virus resistance screening and phenotypic NS3-PI-Resistance characterization. Arevir Meeting, 08./09.05.

Hepatitis C Virus resistance screening and phenotypic NS3-PI-Resistance characterization. Arevir Meeting, 08./09.05. Hepatitis C Virus resistance screening and phenotypic NS3-PI-Resistance characterization Arevir Meeting, 08./09.05.2014 Daniel Rupp HCV prevalence 130-170 million patients world wide Ca. 75% of infections

More information

Hepatitis C Introduction and Overview

Hepatitis C Introduction and Overview Hepatitis C Introduction and Overview Michael S. Saag, MD Professor of Medicine Associate Dean of Global Health Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama

More information

Massimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano. Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future

Massimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano. Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future Massimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future DAA classes and subclasses Drug Class Subclass Potency

More information

2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients

2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients 2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director

More information

Diagnostic Methods of HBV and HDV infections

Diagnostic Methods of HBV and HDV infections Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection

More information

Population Viral Kinetic Modeling: SVR Prediction in HCV GT-3 Cirrhotic Patients With 24 Weeks of Daclatasvir + Sofosbuvir Administration

Population Viral Kinetic Modeling: SVR Prediction in HCV GT-3 Cirrhotic Patients With 24 Weeks of Daclatasvir + Sofosbuvir Administration Population Viral Kinetic Modeling: SVR Prediction in HCV GT-3 Cirrhotic Patients With 24 Weeks of Daclatasvir + Sofosbuvir Administration Emi Tafoya, Yasong Lu, Melody Luo, Premkumar Narasimhan, Neelima

More information

HCV eradication with direct acting antivirals (DAAs)?

HCV eradication with direct acting antivirals (DAAs)? HCV eradication with direct acting antivirals (DAAs)? Emilie Estrabaud Service d Hépatologie et INSERM UMR1149, AP-HP Hôpital Beaujon, Paris, France. emilie.estrabaud@inserm.fr HCV eradication with direct

More information

Individual Optmizaton of therapy. Graham R Foster Professor of Hepatology QMUL

Individual Optmizaton of therapy. Graham R Foster Professor of Hepatology QMUL Individual Optmizaton of therapy Graham R Foster Professor of Hepatology QMUL Conflicts of Interest Speaker and consultancy fees received from AbbVie, BI, BMS, Gilead, Janssen, Roche, Merck, Novarts, Springbank,

More information

A treatment revolution: current management for chronic HCV

A treatment revolution: current management for chronic HCV A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research

More information

Antiviral treatment in HCV cirrhotic patients on waiting list

Antiviral treatment in HCV cirrhotic patients on waiting list Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory

More information

Hepatitis C Update: What s New in 2017

Hepatitis C Update: What s New in 2017 Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu

More information

Genotype 1 Treatment Naïve No Cirrhosis Options

Genotype 1 Treatment Naïve No Cirrhosis Options Genotype 1 Treatment Naïve No Cirrhosis Options Elbasvir/Grazoprevir (Zepatier ) x 12 weeks 1 Glecaprevir/Pibrentasvir (Mavyret ) x 8 weeks Ledipasvir/Sofosbuvir (Harvoni ) x 8-12 weeks 2 1 If genotype

More information

10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives

10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16

More information

NS5A Resistance: Clinical Implications and Treatment Possibilities

NS5A Resistance: Clinical Implications and Treatment Possibilities José Luis Calleja, et al.: NS5A Resistance: Clinical Implications and Treatment Possibilities Contents available at PubMed www.aidsreviews.com AIDS Rev. 2016;18:15-22 NS5A Resistance: Clinical Implications

More information

2017 UnitedHealthcare Services, Inc.

2017 UnitedHealthcare Services, Inc. UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2052-10 Program Prior Authorization/Medical Necessity Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 4/2015, 8/2015,

More information

Introduction. The ELECTRON Trial

Introduction. The ELECTRON Trial 63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver

More information

IFN-free therapy in naïve HCV GT1 patients

IFN-free therapy in naïve HCV GT1 patients IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,

More information

Debate: Do We Need More HCV Drugs Con Standpoint

Debate: Do We Need More HCV Drugs Con Standpoint Debate: Do We Need More HCV Drugs Con Standpoint 18 th Antivirals PK Workshop, Friday 16 th June 2017, Chicago Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany Conflict

More information

Update on chronic hepatitis C treatment: current trends, new challenges, what next?

Update on chronic hepatitis C treatment: current trends, new challenges, what next? Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15

More information

Antivirals for the treatment of chronic HCV infection: Bench to Bedside and beyond

Antivirals for the treatment of chronic HCV infection: Bench to Bedside and beyond Antivirals for the treatment of chronic HCV infection: Bench to Bedside and beyond Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures for

More information

Current trends in CHC 1st genotype treatment

Current trends in CHC 1st genotype treatment Current trends in CHC 1st genotype treatment Tarik Asselah MD, PhD Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France Disclosures Employee of Paris Public University

More information

Treatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.

Treatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D. Session IV Treatment Options in HCV Relapsers and Nonresponders Raymond T. Chung, M.D. Director of Hepatology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston,

More information

Update on Hepatitis C. Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017

Update on Hepatitis C. Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017 Update on Hepatitis C Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017 The global prevalence of HCV was 1 0% (95% uncertainty interval 0 8 1 1) in 2015: 71 1 million (62 5 79

More information

Treatment of Patients with HCV and HIV

Treatment of Patients with HCV and HIV Treatment of Patients with HCV and HIV BRUCE A. LUXON, MD, PHD, FACG ANTON AND MARGARET FUISZ CHAIR IN MEDICINE PROFESSOR AND CHAIRMAN DEPARTMENT OF MEDICINE GEORGETOWN UNIVERSITY Four Questions Is HIV/HCV

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Epclusa) Reference Number: CP.CPA.286 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important

More information

Best of AASLD 2010 For IAGH. April 2011 Reza Malekzadeh M.D. AGAF Professor of Medicne DDRC/TUMS

Best of AASLD 2010 For IAGH. April 2011 Reza Malekzadeh M.D. AGAF Professor of Medicne DDRC/TUMS Best of AASLD 2010 For IAGH April 2011 Reza Malekzadeh M.D. AGAF Professor of Medicne DDRC/TUMS DAAs Direct-Acting Antivirals Understanding of HCV life cycle Identification of potential targets of antivirals

More information

Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4

Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4 Phase 3 Treatment Experienced Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4 Bourlière M, et al. N Engl J Med. 217;376:2134-46. POLARIS-4: Study Features POLARIS-4 Trial Design:

More information

Clinical Criteria for Hepatitis C (HCV) Therapy

Clinical Criteria for Hepatitis C (HCV) Therapy Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy

More information

C-CREST study, Part A: GZR + EBR or MK MK-3682 for genotypes 1, 2 and 3 - Phase II

C-CREST study, Part A: GZR + EBR or MK MK-3682 for genotypes 1, 2 and 3 - Phase II Design 18 years Chronic HCV infection Genotype 1, 2 or 3 Treatment-naïve HCV RNA 1 IU/ml No cirrhosis * No HBV or HIV co-infection Randomisation Open-label * Liver biopsy or Fibroscan 12.5 kpa or Fibrotest

More information

Massimo Puoti Dept. of Infectious Diseases AO Ospedale Niguarda Cà Granda

Massimo Puoti Dept. of Infectious Diseases AO Ospedale Niguarda Cà Granda Massimo Puoti Dept. of Infectious Diseases AO Ospedale Niguarda Cà Granda Innovative strategies in viral hepatitis : Hepatitis C: Interferon and/or Ribavirin free regimens 10th International Workshop on

More information

Hepatitis D. Challenges in 2018

Hepatitis D. Challenges in 2018 Hepatitis D Challenges in 2018 Heiner Wedemeyer Essen University Hospital, Germany Germany Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, AbbVie, Abivax, BMS, Boehringer Ingelheim,

More information

CURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA

CURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and

More information

Clinical Criteria for Hepatitis C (HCV) Therapy

Clinical Criteria for Hepatitis C (HCV) Therapy Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy

More information

Technical Bulletin No. 162

Technical Bulletin No. 162 CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 162 cobas 6800 HCV Viral Load Assay - New Platform - June 1, 2017 Contact: Heather Habig, MLS (ASCP) CM, MB CM, 717-851-1422 Operations

More information

Cases: Management of Hepatitis C in Prior Treatment Failure

Cases: Management of Hepatitis C in Prior Treatment Failure Cases: Management of Hepatitis C in Prior Treatment Failure David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After

More information